Clinical trial
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
NCT04800562 is registered in ClinicalTrials.gov with Processa Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
- Lead sponsor
- Processa Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 12, 2021
- Completion date
- April 14, 2023
- Enrollment
- 4 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.